Loading...
Market
How will Novavax's stock price react to FDA's clinical hold by December 31, 2024?
2
Resolution / Starting Odds
Increases by 10% or more • 25%
Decreases by 10% or more • 25%
Remains within 10% of current value • 25%
Other outcome • 25%
Stock market data from financial news outlets
Story
FDA Places Clinical Hold on Novavax's COVID-19 and Influenza Vaccines Due to Safety Concerns in Phase 3 Trial
Oct 16, 2024, 12:13 PM
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Novavax's COVID-19 and influenza combination vaccine, as well as its standalone influenza vaccine candidates due to safety concerns. This decision comes after a spontaneous report of a serious adverse event (SAE) involving motor neuropathy. The clinical hold affects the Investigational New Drug (IND) applications for these vaccines, which were in Phase 3 Trial.
View original story
Similar markets
Increases by more than 20% • 25%
Increases by 10% to 20% • 25%
Stays within +/- 10% • 25%
Decreases by more than 10% • 25%
Yes • 50%
No • 50%
Clinical hold lifted with no changes • 25%
Clinical hold lifted with additional requirements • 25%
Clinical hold maintained • 25%
Clinical hold converted to full stop • 25%
Increase by more than 20% • 25%
Increase by 0-20% • 25%
Decrease by 0-20% • 25%
Decrease by more than 20% • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Hold lifted with no conditions • 25%
Hold lifted with conditions • 25%
Hold extended • 25%
Hold converted to permanent suspension • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%